Single domain antibodies: Promising experimental and therapeutic tools in infection and immunity

Autores
Wesolowski, Janusz; Alzogaray, Vanina Andrea; Reyelt, Jan; Unger, Mandy; Juarez, Karla; Urrutia, Mariela; Cauerhff, Ana; Danquah, Welbeck; Rissiek, Björn; Scheuplein, Felix; Schwarz, Nicole; Adriouch, Sahil; Boyer, Olivier; Seman, Michel; Licea, Alexei; Serreze, David V.; Goldbaum, Fernando Alberto; Haag, Friedrich; Koch Nolte, Friedrich
Año de publicación
2009
Idioma
inglés
Tipo de recurso
artículo
Estado
versión publicada
Descripción
Antibodies are important tools for experimental research and medical applications. Most antibodies are composed of two heavy and two light chains. Both chains contribute to the antigen-binding site which is usually flat or concave. In addition to these conventional antibodies, llamas, other camelids, and sharks also produce antibodies composed only of heavy chains. The antigen-binding site of these unusual heavy chain antibodies (hcAbs) is formed only by a single domain, designated VHH in camelid hcAbs and VNAR in shark hcAbs. VHH and VNAR are easily produced as recombinant proteins, designated single domain antibodies (sdAbs) or nanobodies. The CDR3 region of these sdAbs possesses the extraordinary capacity to form long fingerlike extensions that can extend into cavities on antigens, e.g., the active site crevice of enzymes. Other advantageous features of nanobodies include their small size, high solubility, thermal stability, refolding capacity, and good tissue penetration in vivo. Here we review the results of several recent proof-of-principle studies that open the exciting perspective of using sdAbs for modulating immune functions and for targeting toxins and microbes.
Fil: Wesolowski, Janusz. Universitatsklinikum Hamburg-eppendorf Und Medizinische Fakultat; Alemania
Fil: Alzogaray, Vanina Andrea. Consejo Nacional de Investigaciones Científicas y Técnicas. Oficina de Coordinación Administrativa Parque Centenario. Instituto de Investigaciones Bioquímicas de Buenos Aires. Fundación Instituto Leloir. Instituto de Investigaciones Bioquímicas de Buenos Aires; Argentina
Fil: Reyelt, Jan. Universitatsklinikum Hamburg-eppendorf Und Medizinische Fakultat; Alemania
Fil: Unger, Mandy. Universitatsklinikum Hamburg-eppendorf Und Medizinische Fakultat; Alemania
Fil: Juarez, Karla. Universitatsklinikum Hamburg-eppendorf Und Medizinische Fakultat; Alemania. Centro de Investigacion Cientifica y de Educacion Superior de Ensenada; México
Fil: Urrutia, Mariela. Consejo Nacional de Investigaciones Científicas y Técnicas. Oficina de Coordinación Administrativa Parque Centenario. Instituto de Investigaciones Bioquímicas de Buenos Aires. Fundación Instituto Leloir. Instituto de Investigaciones Bioquímicas de Buenos Aires; Argentina
Fil: Cauerhff, Ana. Consejo Nacional de Investigaciones Científicas y Técnicas. Oficina de Coordinación Administrativa Parque Centenario. Instituto de Investigaciones Bioquímicas de Buenos Aires. Fundación Instituto Leloir. Instituto de Investigaciones Bioquímicas de Buenos Aires; Argentina
Fil: Danquah, Welbeck. Universitatsklinikum Hamburg-eppendorf Und Medizinische Fakultat; Alemania
Fil: Rissiek, Björn. Universitatsklinikum Hamburg-eppendorf Und Medizinische Fakultat; Alemania
Fil: Scheuplein, Felix. Universitatsklinikum Hamburg-eppendorf Und Medizinische Fakultat; Alemania
Fil: Schwarz, Nicole. Universitatsklinikum Hamburg-eppendorf Und Medizinische Fakultat; Alemania
Fil: Adriouch, Sahil. Chu Hopitaux de Rouen; Francia
Fil: Boyer, Olivier. Chu Hopitaux de Rouen; Francia
Fil: Seman, Michel. Chu Hopitaux de Rouen; Francia
Fil: Licea, Alexei. Centro de Investigacion Cientifica y de Educacion Superior de Ensenada; México
Fil: Serreze, David V.. Jackson Laboratory; Estados Unidos
Fil: Goldbaum, Fernando Alberto. Consejo Nacional de Investigaciones Científicas y Técnicas. Oficina de Coordinación Administrativa Parque Centenario. Instituto de Investigaciones Bioquímicas de Buenos Aires. Fundación Instituto Leloir. Instituto de Investigaciones Bioquímicas de Buenos Aires; Argentina
Fil: Haag, Friedrich. Universitatsklinikum Hamburg-eppendorf Und Medizinische Fakultat; Alemania
Fil: Koch Nolte, Friedrich. Universitatsklinikum Hamburg-eppendorf Und Medizinische Fakultat; Alemania
Materia
Enzyme Inhibitors
Nanobody
Recombinant Antibodies
Single Domain Antibodies
Vhh
Virus Neutralization
Nivel de accesibilidad
acceso abierto
Condiciones de uso
https://creativecommons.org/licenses/by-nc/2.5/ar/
Repositorio
CONICET Digital (CONICET)
Institución
Consejo Nacional de Investigaciones Científicas y Técnicas
OAI Identificador
oai:ri.conicet.gov.ar:11336/36849
Acceder
id CONICETDig_837d9b4de7409ca29db9ca16d58f20c7
oai_identifier_str oai:ri.conicet.gov.ar:11336/36849
network_acronym_str CONICETDig
repository_id_str 3498
network_name_str CONICET Digital (CONICET)
spelling Single domain antibodies: Promising experimental and therapeutic tools in infection and immunityWesolowski, JanuszAlzogaray, Vanina AndreaReyelt, JanUnger, MandyJuarez, KarlaUrrutia, MarielaCauerhff, AnaDanquah, WelbeckRissiek, BjörnScheuplein, FelixSchwarz, NicoleAdriouch, SahilBoyer, OlivierSeman, MichelLicea, AlexeiSerreze, David V.Goldbaum, Fernando AlbertoHaag, FriedrichKoch Nolte, FriedrichEnzyme InhibitorsNanobodyRecombinant AntibodiesSingle Domain AntibodiesVhhVirus NeutralizationAntibodies are important tools for experimental research and medical applications. Most antibodies are composed of two heavy and two light chains. Both chains contribute to the antigen-binding site which is usually flat or concave. In addition to these conventional antibodies, llamas, other camelids, and sharks also produce antibodies composed only of heavy chains. The antigen-binding site of these unusual heavy chain antibodies (hcAbs) is formed only by a single domain, designated VHH in camelid hcAbs and VNAR in shark hcAbs. VHH and VNAR are easily produced as recombinant proteins, designated single domain antibodies (sdAbs) or nanobodies. The CDR3 region of these sdAbs possesses the extraordinary capacity to form long fingerlike extensions that can extend into cavities on antigens, e.g., the active site crevice of enzymes. Other advantageous features of nanobodies include their small size, high solubility, thermal stability, refolding capacity, and good tissue penetration in vivo. Here we review the results of several recent proof-of-principle studies that open the exciting perspective of using sdAbs for modulating immune functions and for targeting toxins and microbes.Fil: Wesolowski, Janusz. Universitatsklinikum Hamburg-eppendorf Und Medizinische Fakultat; AlemaniaFil: Alzogaray, Vanina Andrea. Consejo Nacional de Investigaciones Científicas y Técnicas. Oficina de Coordinación Administrativa Parque Centenario. Instituto de Investigaciones Bioquímicas de Buenos Aires. Fundación Instituto Leloir. Instituto de Investigaciones Bioquímicas de Buenos Aires; ArgentinaFil: Reyelt, Jan. Universitatsklinikum Hamburg-eppendorf Und Medizinische Fakultat; AlemaniaFil: Unger, Mandy. Universitatsklinikum Hamburg-eppendorf Und Medizinische Fakultat; AlemaniaFil: Juarez, Karla. Universitatsklinikum Hamburg-eppendorf Und Medizinische Fakultat; Alemania. Centro de Investigacion Cientifica y de Educacion Superior de Ensenada; MéxicoFil: Urrutia, Mariela. Consejo Nacional de Investigaciones Científicas y Técnicas. Oficina de Coordinación Administrativa Parque Centenario. Instituto de Investigaciones Bioquímicas de Buenos Aires. Fundación Instituto Leloir. Instituto de Investigaciones Bioquímicas de Buenos Aires; ArgentinaFil: Cauerhff, Ana. Consejo Nacional de Investigaciones Científicas y Técnicas. Oficina de Coordinación Administrativa Parque Centenario. Instituto de Investigaciones Bioquímicas de Buenos Aires. Fundación Instituto Leloir. Instituto de Investigaciones Bioquímicas de Buenos Aires; ArgentinaFil: Danquah, Welbeck. Universitatsklinikum Hamburg-eppendorf Und Medizinische Fakultat; AlemaniaFil: Rissiek, Björn. Universitatsklinikum Hamburg-eppendorf Und Medizinische Fakultat; AlemaniaFil: Scheuplein, Felix. Universitatsklinikum Hamburg-eppendorf Und Medizinische Fakultat; AlemaniaFil: Schwarz, Nicole. Universitatsklinikum Hamburg-eppendorf Und Medizinische Fakultat; AlemaniaFil: Adriouch, Sahil. Chu Hopitaux de Rouen; FranciaFil: Boyer, Olivier. Chu Hopitaux de Rouen; FranciaFil: Seman, Michel. Chu Hopitaux de Rouen; FranciaFil: Licea, Alexei. Centro de Investigacion Cientifica y de Educacion Superior de Ensenada; MéxicoFil: Serreze, David V.. Jackson Laboratory; Estados UnidosFil: Goldbaum, Fernando Alberto. Consejo Nacional de Investigaciones Científicas y Técnicas. Oficina de Coordinación Administrativa Parque Centenario. Instituto de Investigaciones Bioquímicas de Buenos Aires. Fundación Instituto Leloir. Instituto de Investigaciones Bioquímicas de Buenos Aires; ArgentinaFil: Haag, Friedrich. Universitatsklinikum Hamburg-eppendorf Und Medizinische Fakultat; AlemaniaFil: Koch Nolte, Friedrich. Universitatsklinikum Hamburg-eppendorf Und Medizinische Fakultat; AlemaniaSpringer2009-08info:eu-repo/semantics/articleinfo:eu-repo/semantics/publishedVersionhttp://purl.org/coar/resource_type/c_6501info:ar-repo/semantics/articuloapplication/pdfapplication/pdfapplication/pdfapplication/pdfapplication/pdfapplication/pdfhttp://hdl.handle.net/11336/36849Wesolowski, Janusz; Alzogaray, Vanina Andrea; Reyelt, Jan; Unger, Mandy; Juarez, Karla; et al.; Single domain antibodies: Promising experimental and therapeutic tools in infection and immunity; Springer; Medical Microbiology and Immunology; 198; 3; 8-2009; 157-1740300-8584CONICET DigitalCONICETenginfo:eu-repo/semantics/altIdentifier/url/https://link.springer.com/article/10.1007%2Fs00430-009-0116-7info:eu-repo/semantics/altIdentifier/doi/10.1007/s00430-009-0116-7info:eu-repo/semantics/openAccesshttps://creativecommons.org/licenses/by-nc/2.5/ar/reponame:CONICET Digital (CONICET)instname:Consejo Nacional de Investigaciones Científicas y Técnicas2025-10-15T14:28:25Zoai:ri.conicet.gov.ar:11336/36849instacron:CONICETInstitucionalhttp://ri.conicet.gov.ar/Organismo científico-tecnológicoNo correspondehttp://ri.conicet.gov.ar/oai/requestdasensio@conicet.gov.ar; lcarlino@conicet.gov.arArgentinaNo correspondeNo correspondeNo correspondeopendoar:34982025-10-15 14:28:25.789CONICET Digital (CONICET) - Consejo Nacional de Investigaciones Científicas y Técnicasfalse
dc.title.none.fl_str_mv Single domain antibodies: Promising experimental and therapeutic tools in infection and immunity
title Single domain antibodies: Promising experimental and therapeutic tools in infection and immunity
spellingShingle Single domain antibodies: Promising experimental and therapeutic tools in infection and immunity
Wesolowski, Janusz
Enzyme Inhibitors
Nanobody
Recombinant Antibodies
Single Domain Antibodies
Vhh
Virus Neutralization
title_short Single domain antibodies: Promising experimental and therapeutic tools in infection and immunity
title_full Single domain antibodies: Promising experimental and therapeutic tools in infection and immunity
title_fullStr Single domain antibodies: Promising experimental and therapeutic tools in infection and immunity
title_full_unstemmed Single domain antibodies: Promising experimental and therapeutic tools in infection and immunity
title_sort Single domain antibodies: Promising experimental and therapeutic tools in infection and immunity
dc.creator.none.fl_str_mv Wesolowski, Janusz
Alzogaray, Vanina Andrea
Reyelt, Jan
Unger, Mandy
Juarez, Karla
Urrutia, Mariela
Cauerhff, Ana
Danquah, Welbeck
Rissiek, Björn
Scheuplein, Felix
Schwarz, Nicole
Adriouch, Sahil
Boyer, Olivier
Seman, Michel
Licea, Alexei
Serreze, David V.
Goldbaum, Fernando Alberto
Haag, Friedrich
Koch Nolte, Friedrich
author Wesolowski, Janusz
author_facet Wesolowski, Janusz
Alzogaray, Vanina Andrea
Reyelt, Jan
Unger, Mandy
Juarez, Karla
Urrutia, Mariela
Cauerhff, Ana
Danquah, Welbeck
Rissiek, Björn
Scheuplein, Felix
Schwarz, Nicole
Adriouch, Sahil
Boyer, Olivier
Seman, Michel
Licea, Alexei
Serreze, David V.
Goldbaum, Fernando Alberto
Haag, Friedrich
Koch Nolte, Friedrich
author_role author
author2 Alzogaray, Vanina Andrea
Reyelt, Jan
Unger, Mandy
Juarez, Karla
Urrutia, Mariela
Cauerhff, Ana
Danquah, Welbeck
Rissiek, Björn
Scheuplein, Felix
Schwarz, Nicole
Adriouch, Sahil
Boyer, Olivier
Seman, Michel
Licea, Alexei
Serreze, David V.
Goldbaum, Fernando Alberto
Haag, Friedrich
Koch Nolte, Friedrich
author2_role author
author
author
author
author
author
author
author
author
author
author
author
author
author
author
author
author
author
dc.subject.none.fl_str_mv Enzyme Inhibitors
Nanobody
Recombinant Antibodies
Single Domain Antibodies
Vhh
Virus Neutralization
topic Enzyme Inhibitors
Nanobody
Recombinant Antibodies
Single Domain Antibodies
Vhh
Virus Neutralization
dc.description.none.fl_txt_mv Antibodies are important tools for experimental research and medical applications. Most antibodies are composed of two heavy and two light chains. Both chains contribute to the antigen-binding site which is usually flat or concave. In addition to these conventional antibodies, llamas, other camelids, and sharks also produce antibodies composed only of heavy chains. The antigen-binding site of these unusual heavy chain antibodies (hcAbs) is formed only by a single domain, designated VHH in camelid hcAbs and VNAR in shark hcAbs. VHH and VNAR are easily produced as recombinant proteins, designated single domain antibodies (sdAbs) or nanobodies. The CDR3 region of these sdAbs possesses the extraordinary capacity to form long fingerlike extensions that can extend into cavities on antigens, e.g., the active site crevice of enzymes. Other advantageous features of nanobodies include their small size, high solubility, thermal stability, refolding capacity, and good tissue penetration in vivo. Here we review the results of several recent proof-of-principle studies that open the exciting perspective of using sdAbs for modulating immune functions and for targeting toxins and microbes.
Fil: Wesolowski, Janusz. Universitatsklinikum Hamburg-eppendorf Und Medizinische Fakultat; Alemania
Fil: Alzogaray, Vanina Andrea. Consejo Nacional de Investigaciones Científicas y Técnicas. Oficina de Coordinación Administrativa Parque Centenario. Instituto de Investigaciones Bioquímicas de Buenos Aires. Fundación Instituto Leloir. Instituto de Investigaciones Bioquímicas de Buenos Aires; Argentina
Fil: Reyelt, Jan. Universitatsklinikum Hamburg-eppendorf Und Medizinische Fakultat; Alemania
Fil: Unger, Mandy. Universitatsklinikum Hamburg-eppendorf Und Medizinische Fakultat; Alemania
Fil: Juarez, Karla. Universitatsklinikum Hamburg-eppendorf Und Medizinische Fakultat; Alemania. Centro de Investigacion Cientifica y de Educacion Superior de Ensenada; México
Fil: Urrutia, Mariela. Consejo Nacional de Investigaciones Científicas y Técnicas. Oficina de Coordinación Administrativa Parque Centenario. Instituto de Investigaciones Bioquímicas de Buenos Aires. Fundación Instituto Leloir. Instituto de Investigaciones Bioquímicas de Buenos Aires; Argentina
Fil: Cauerhff, Ana. Consejo Nacional de Investigaciones Científicas y Técnicas. Oficina de Coordinación Administrativa Parque Centenario. Instituto de Investigaciones Bioquímicas de Buenos Aires. Fundación Instituto Leloir. Instituto de Investigaciones Bioquímicas de Buenos Aires; Argentina
Fil: Danquah, Welbeck. Universitatsklinikum Hamburg-eppendorf Und Medizinische Fakultat; Alemania
Fil: Rissiek, Björn. Universitatsklinikum Hamburg-eppendorf Und Medizinische Fakultat; Alemania
Fil: Scheuplein, Felix. Universitatsklinikum Hamburg-eppendorf Und Medizinische Fakultat; Alemania
Fil: Schwarz, Nicole. Universitatsklinikum Hamburg-eppendorf Und Medizinische Fakultat; Alemania
Fil: Adriouch, Sahil. Chu Hopitaux de Rouen; Francia
Fil: Boyer, Olivier. Chu Hopitaux de Rouen; Francia
Fil: Seman, Michel. Chu Hopitaux de Rouen; Francia
Fil: Licea, Alexei. Centro de Investigacion Cientifica y de Educacion Superior de Ensenada; México
Fil: Serreze, David V.. Jackson Laboratory; Estados Unidos
Fil: Goldbaum, Fernando Alberto. Consejo Nacional de Investigaciones Científicas y Técnicas. Oficina de Coordinación Administrativa Parque Centenario. Instituto de Investigaciones Bioquímicas de Buenos Aires. Fundación Instituto Leloir. Instituto de Investigaciones Bioquímicas de Buenos Aires; Argentina
Fil: Haag, Friedrich. Universitatsklinikum Hamburg-eppendorf Und Medizinische Fakultat; Alemania
Fil: Koch Nolte, Friedrich. Universitatsklinikum Hamburg-eppendorf Und Medizinische Fakultat; Alemania
description Antibodies are important tools for experimental research and medical applications. Most antibodies are composed of two heavy and two light chains. Both chains contribute to the antigen-binding site which is usually flat or concave. In addition to these conventional antibodies, llamas, other camelids, and sharks also produce antibodies composed only of heavy chains. The antigen-binding site of these unusual heavy chain antibodies (hcAbs) is formed only by a single domain, designated VHH in camelid hcAbs and VNAR in shark hcAbs. VHH and VNAR are easily produced as recombinant proteins, designated single domain antibodies (sdAbs) or nanobodies. The CDR3 region of these sdAbs possesses the extraordinary capacity to form long fingerlike extensions that can extend into cavities on antigens, e.g., the active site crevice of enzymes. Other advantageous features of nanobodies include their small size, high solubility, thermal stability, refolding capacity, and good tissue penetration in vivo. Here we review the results of several recent proof-of-principle studies that open the exciting perspective of using sdAbs for modulating immune functions and for targeting toxins and microbes.
publishDate 2009
dc.date.none.fl_str_mv 2009-08
dc.type.none.fl_str_mv info:eu-repo/semantics/article
info:eu-repo/semantics/publishedVersion
http://purl.org/coar/resource_type/c_6501
info:ar-repo/semantics/articulo
format article
status_str publishedVersion
dc.identifier.none.fl_str_mv http://hdl.handle.net/11336/36849
Wesolowski, Janusz; Alzogaray, Vanina Andrea; Reyelt, Jan; Unger, Mandy; Juarez, Karla; et al.; Single domain antibodies: Promising experimental and therapeutic tools in infection and immunity; Springer; Medical Microbiology and Immunology; 198; 3; 8-2009; 157-174
0300-8584
CONICET Digital
CONICET
url http://hdl.handle.net/11336/36849
identifier_str_mv Wesolowski, Janusz; Alzogaray, Vanina Andrea; Reyelt, Jan; Unger, Mandy; Juarez, Karla; et al.; Single domain antibodies: Promising experimental and therapeutic tools in infection and immunity; Springer; Medical Microbiology and Immunology; 198; 3; 8-2009; 157-174
0300-8584
CONICET Digital
CONICET
dc.language.none.fl_str_mv eng
language eng
dc.relation.none.fl_str_mv info:eu-repo/semantics/altIdentifier/url/https://link.springer.com/article/10.1007%2Fs00430-009-0116-7
info:eu-repo/semantics/altIdentifier/doi/10.1007/s00430-009-0116-7
dc.rights.none.fl_str_mv info:eu-repo/semantics/openAccess
https://creativecommons.org/licenses/by-nc/2.5/ar/
eu_rights_str_mv openAccess
rights_invalid_str_mv https://creativecommons.org/licenses/by-nc/2.5/ar/
dc.format.none.fl_str_mv application/pdf
application/pdf
application/pdf
application/pdf
application/pdf
application/pdf
dc.publisher.none.fl_str_mv Springer
publisher.none.fl_str_mv Springer
dc.source.none.fl_str_mv reponame:CONICET Digital (CONICET)
instname:Consejo Nacional de Investigaciones Científicas y Técnicas
reponame_str CONICET Digital (CONICET)
collection CONICET Digital (CONICET)
instname_str Consejo Nacional de Investigaciones Científicas y Técnicas
repository.name.fl_str_mv CONICET Digital (CONICET) - Consejo Nacional de Investigaciones Científicas y Técnicas
repository.mail.fl_str_mv dasensio@conicet.gov.ar; lcarlino@conicet.gov.ar
_version_ 1846082747817263104
score 13.22299

Publicaciones similares